{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T15:37:16Z","timestamp":1785253036209,"version":"3.55.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.msard.2023.104719","type":"journal-article","created":{"date-parts":[[2023,4,16]],"date-time":"2023-04-16T09:25:27Z","timestamp":1681637127000},"page":"104719","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Teriflunomide modulates both innate and adaptive immune capacities in multiple sclerosis"],"prefix":"10.1016","volume":"75","author":[{"given":"Qi","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8149-5161","authenticated-orcid":false,"given":"Jennifer","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Mills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavani","family":"Chilukuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiya","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine A.","family":"Dowling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlyn","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany","family":"Kirch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Mao-Draayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"14","key":"10.1016\/j.msard.2023.104719_bib0001","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1056\/NEJMoa1014656","article-title":"Randomized trial of oral teriflunomide for relapsing multiple sclerosis","volume":"365","author":"O'Connor","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2023.104719_bib0002","series-title":"presented at: 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)","article-title":"The efficacy and safety of teriflunomide in patients with relapsing MS: results from TOWER, a phase III, placebo-controlled study","author":"Kappos","year":"2012"},{"issue":"1\u20132","key":"10.1016\/j.msard.2023.104719_bib0003","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jneuroim.2013.10.003","article-title":"The effects of teriflunomide on lymphocyte subpopulations in human peripheral blood mononuclear cells in vitro","volume":"265","author":"Li","year":"2013","journal-title":"J. Neuroimmunol."},{"issue":"1","key":"10.1016\/j.msard.2023.104719_bib0004","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.clim.2011.02.011","article-title":"Immune mechanisms of new therapeutic strategies in MS: teriflunomide","volume":"142","author":"Claussen","year":"2012","journal-title":"Clin. Immunol."},{"issue":"11","key":"10.1016\/j.msard.2023.104719_bib0005","doi-asserted-by":"crossref","first-page":"R1136","DOI":"10.1152\/ajpregu.00315.2012","article-title":"Aryl hydrocarbon receptor agonist, leflunomide, protects the ischemic-reperfused kidney: role of Tregs and stem cells","volume":"303","author":"Baban","year":"2012","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"issue":"5","key":"10.1016\/j.msard.2023.104719_bib0006","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1189\/jlb.0504308","article-title":"Modulation of effector cell functions in experimental autoimmune encephalomyelitis by leflunomide\u2013mechanisms independent of pyrimidine depletion","volume":"76","author":"Korn","year":"2004","journal-title":"J. Leukoc. Biol."},{"issue":"7","key":"10.1016\/j.msard.2023.104719_bib0007","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1038\/sj.jid.5700228","article-title":"Induction of regulatory T cells by leflunomide in a murine model of contact allergen sensitivity","volume":"126","author":"Weigmann","year":"2006","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.msard.2023.104719_bib0008","article-title":"Teriflunomide treatment for multiple sclerosis modulates T cell mitochondrial respiration with affinity-dependent effects","volume":"05","author":"Klotz","year":"2019","journal-title":"Sci. Transl. Med."},{"issue":"8","key":"10.1016\/j.msard.2023.104719_bib0009","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.4049\/jimmunol.1601532","article-title":"Dimethyl fumarate selectively reduces memory T cells and shifts the balance between Th1\/Th17 and Th2 in multiple sclerosis patients","volume":"198","author":"Wu","year":"2017","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.msard.2023.104719_bib0010","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.134251","article-title":"Siponimod enriches regulatory T and B lymphocytes in secondary progressive multiple sclerosis","volume":"5","author":"Wu","year":"2020","journal-title":"JCI Insight"},{"issue":"2","key":"10.1016\/j.msard.2023.104719_bib0011","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/acn3.711","article-title":"Teriflunomide induces a tolerogenic bias in blood immune cells of MS patients","volume":"6","author":"Medina","year":"2019","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"6","key":"10.1016\/j.msard.2023.104719_bib0012","doi-asserted-by":"crossref","first-page":"874","DOI":"10.2174\/1570159X14666161208151525","article-title":"From leflunomide to teriflunomide: drug development and immunosuppressive oral drugs in the treatment of multiple sclerosis","volume":"15","author":"Aly","year":"2017","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.msard.2023.104719_bib0013","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.86.16_supplement.P5.282","article-title":"TERI-DYNAMIC: exploring the impact of teriflunomide on immune cell population size, receptor repertoire, and function in patients with RRMS (P50.282)","volume":"86","author":"Wiendl","year":"2016","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.msard.2023.104719_bib0014","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.4049\/jimmunol.169.6.3392","article-title":"Restriction of de novo pyrimidine biosynthesis inhibits Th1 cell activation and promotes Th2 cell differentiation","volume":"169","author":"Dimitrova","year":"2002","journal-title":"J. Immunol."},{"issue":"6","key":"10.1016\/j.msard.2023.104719_bib0015","doi-asserted-by":"crossref","first-page":"e403","DOI":"10.1212\/NXI.0000000000000403","article-title":"Teriflunomide treatment reduces B cells in patients with MS","volume":"4","author":"Gandoglia","year":"2017","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2023.104719_bib0016","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.730342","article-title":"Teriflunomide Treatment of Multiple Sclerosis Selectively Modulates CD8 Memory T Cells","volume":"12","author":"Tilly","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.msard.2023.104719_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.tox.2018.02.003","article-title":"Mitochondrial dysfunction induced by leflunomide and its active metabolite","author":"Xuan","year":"2018","journal-title":"Toxicology"},{"key":"10.1016\/j.msard.2023.104719_bib0018","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.718863","article-title":"Mitochondrial-linked de novo pyrimidine biosynthesis dictates human T-cell proliferation but not expression of effector molecules","volume":"12","author":"Peeters","year":"2021","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.msard.2023.104719_bib0019","doi-asserted-by":"crossref","first-page":"e291","DOI":"10.1212\/NXI.0000000000000291","article-title":"Induction of gut regulatory CD39(+) T cells by teriflunomide protects against EAE","volume":"3","author":"Ochoa-Reparaz","year":"2016","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"9","key":"10.1016\/j.msard.2023.104719_bib0020","doi-asserted-by":"crossref","first-page":"4808","DOI":"10.1007\/s00415-022-11118-7","article-title":"Real-world outcomes of teriflunomide in relapsing-remitting multiple sclerosis: a prospective cohort study","volume":"269","author":"Zhang","year":"2022","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2023.104719_bib0021","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.clim.2017.04.014","article-title":"Effector and regulatory B cells in multiple sclerosis","volume":"184","author":"Staun-Ram","year":"2017","journal-title":"Clin. Immunol."},{"issue":"9","key":"10.1016\/j.msard.2023.104719_bib0022","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.1182\/blood-2004-09-3740","article-title":"B-cell kinetics in humans: rapid turnover of peripheral blood memory cells","volume":"105","author":"Macallan","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.msard.2023.104719_bib0023","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3389\/fimmu.2015.00455","article-title":"\u03b3\u03b4 T cells and NK cells - distinct pathogenic roles as innate-like immune cells in CNS autoimmunity","volume":"6","author":"Edwards","year":"2015","journal-title":"Front. Immunol."},{"issue":"1\u20132","key":"10.1016\/j.msard.2023.104719_bib0024","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jneuroim.2013.10.004","article-title":"Circulating CD56dim NK cells expressing perforin are increased in progressive multiple sclerosis","volume":"265","author":"Plantone","year":"2013","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2023.104719_bib0025","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3389\/fimmu.2013.00063","article-title":"The role of natural killer cells in multiple sclerosis and their therapeutic implications","volume":"4","author":"Chanvillard","year":"2013","journal-title":"Front. Immunol."},{"key":"10.1016\/j.msard.2023.104719_bib0026","article-title":"Optimal response to dimethyl fumarate associates in MS with a shift from an inflammatory to a tolerogenic blood cell profile","author":"Medina","year":"2017","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2023.104719_bib0027","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3389\/fimmu.2016.00437","article-title":"Glatiramer Acetate, Dimethyl Fumarate, and Monomethyl Fumarate Upregulate the Expression of CCR10 on the Surface of Natural Killer Cells and Enhance Their Chemotaxis and Cytotoxicity","volume":"7","author":"Maghazachi","year":"2016","journal-title":"Front. Immunol."},{"key":"10.1016\/j.msard.2023.104719_bib0028","first-page":"229","article-title":"Pharmacology and clinical efficacy of dimethyl fumarate (BG-12) for treatment of relapsing-remitting multiple sclerosis","volume":"10","author":"Ruggieri","year":"2014","journal-title":"Ther. Clin. Risk Manag."},{"issue":"7","key":"10.1016\/j.msard.2023.104719_bib0029","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1111\/ijd.12834","article-title":"The effect of dimethyl fumarate on gene expression and the level of cytokines related to different T helper cell subsets in peripheral blood mononuclear cells of patients with psoriasis","volume":"54","author":"Tahvili","year":"2015","journal-title":"Int. J. Dermatol."},{"issue":"1","key":"10.1016\/j.msard.2023.104719_bib0030","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/cmi.2014.114","article-title":"Monomethyl fumarate augments NK cell lysis of tumor cells through degranulation and the upregulation of NKp46 and CD107a","volume":"13","author":"Vego","year":"2016","journal-title":"Cell Mol. Immunol."},{"key":"10.1016\/j.msard.2023.104719_bib0031","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3389\/fimmu.2018.00367","article-title":"The role of natural killer T cells in cancer-a phenotypical and functional approach","volume":"9","author":"Krijgsman","year":"2018","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.msard.2023.104719_bib0032","doi-asserted-by":"crossref","first-page":"e489","DOI":"10.1002\/hsr2.489","article-title":"The role of NK and NKT cells in the pathogenesis and improvement of multiple sclerosis following disease-modifying therapies","volume":"5","author":"Ahmadi","year":"2022","journal-title":"Health Sci. Rep."},{"key":"10.1016\/j.msard.2023.104719_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2020.577323","article-title":"The peripheral blood immune cell profile in a teriflunomide-treated multiple sclerosis patient with COVID-19 pneumonia","volume":"346","author":"Ciardi","year":"2020","journal-title":"J. Neuroimmunol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823002237?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823002237?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:07:36Z","timestamp":1761901656000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034823002237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":33,"alternative-id":["S2211034823002237"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2023.104719","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Teriflunomide modulates both innate and adaptive immune capacities in multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2023.104719","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104719"}}